Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Other Topics

Abstract A170: The mode of action of Orf virus – a novel viral vector for therapeutic cancer vaccines

Melanie Mueller, Ralf Amann, Thomas Feger and Hans-Georg Rammensee
Melanie Mueller
Immunology, Tuebingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralf Amann
Immunology, Tuebingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Feger
Immunology, Tuebingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Georg Rammensee
Immunology, Tuebingen, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-A170 Published January 2016
  • Article
  • Info & Metrics
Loading
Abstracts: CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY

Abstract

Viral vector vaccines still represent most excellent inducers of cell-mediated and humoral immune responses. Therefore, intensive investigations are performed to improve the use of several virus families as safe and efficient viral vectors, not only against diverse infectious diseases but also against tumors. During the last decade we developed a novel vector virus platform using Orf virus (ORFV), a member of the genus Parapoxvirus of Poxviridae. The attractiveness of an ORFV vector rely on the following advantages: (i) a very restricted host range, (ii) no evidence for viral systemic spread, (iii) the fast induction of humoral and cellular immune responses, especially also in non-permissive hosts that do not support vector replication, (iv) a short-term vector-specific immunity allowing multiple re-immunizations, and (v) the possibility to generate recombinants by targeted deletion of ORFV virulence genes on the basis of the highly attenuated, apathogenic ORFV strain D1701-V.

Recently, we were able to demonstrate the excellent immune stimulating (humoral and cellular) and prophylactic capacity of ORFV-based recombinants against numerous different viral diseases manifold. Obviously, it would be of great interest, if ORFV might serve as a platform for the development of therapeutic tumor vaccines for humans. Hence, we would like to investigate the so far poorly understood mechanism of immune stimulation and -induction as well as the possibilities to further manipulate/trigger the induced immune response by co-expression of immune regulating factors more precise.

With the aid of a recombinant ORFV expressing the fluorescent marker protein mCherry, the mode of action and the immune cells involved in this immune activation is investigated. In a first step, freshly isolated human PBMC subpopulations were infected at different time points and with different MOIs (multiplicity of infections) and the infection rate and cell viability were measured. Thereby we observed that professional antigen presenting cells (APC) were most susceptible for infection/uptake of virus. Next we wanted to investigate the activation status of the APCs. Therefore we analyzed the effect of ORFV on the expression of surface markerswhich are important for antigen-presentation and co-stimulation of T-cells (e.g. HLA DR, CD40, CD80 and CD86). In a further step we examined the cytokine release to elucidate the effects of ORFV infection on the immune stimulatory capacity of APCs.

The capability to cause T-cell priming, as an integral part of the immune activation, will be studied more precisely using the model antigens Melan A and pp65 (hCMV). Further optimization of the immune stimulatory capabilities of ORFV shall be achieved by co-expression of adequate cytokines together with the integrated model antigen.

Citation Format: Melanie Mueller, Ralf Amann, Thomas Feger, Hans-Georg Rammensee. The mode of action of Orf virus – a novel viral vector for therapeutic cancer vaccines. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr A170.

  • ©2016 American Association for Cancer Research.
Previous
Back to top
Cancer Immunology Research: 4 (1 Supplement)
January 2016
Volume 4, Issue 1 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A170: The mode of action of Orf virus – a novel viral vector for therapeutic cancer vaccines
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A170: The mode of action of Orf virus – a novel viral vector for therapeutic cancer vaccines
Melanie Mueller, Ralf Amann, Thomas Feger and Hans-Georg Rammensee
Cancer Immunol Res January 1 2016 (4) (1 Supplement) A170; DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-A170

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A170: The mode of action of Orf virus – a novel viral vector for therapeutic cancer vaccines
Melanie Mueller, Ralf Amann, Thomas Feger and Hans-Georg Rammensee
Cancer Immunol Res January 1 2016 (4) (1 Supplement) A170; DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-A170
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Other Topics

  • Abstract B170: Therapeutic implications of altered epigenetics and DNA damage responses in IDH2-mutated hematologic diseases
  • Abstract B197: Translational control in macrophages during inflammatory response
  • Abstract B200: Single-cell RNA-sequencing (ScRNA-seq) reveals broad heterogeneity among CD8 T-cells during chronic viral infection and identifies a critical role for CD4 help in promoting the differentiation of a potent cytotoxic CD8 T-cell subset
Show more Other Topics

Other Topics: Poster Presentations - Proffered Abstracts

  • Abstract B170: Therapeutic implications of altered epigenetics and DNA damage responses in IDH2-mutated hematologic diseases
  • Abstract B197: Translational control in macrophages during inflammatory response
  • Abstract B200: Single-cell RNA-sequencing (ScRNA-seq) reveals broad heterogeneity among CD8 T-cells during chronic viral infection and identifies a critical role for CD4 help in promoting the differentiation of a potent cytotoxic CD8 T-cell subset
Show more Other Topics: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement